Health news: stem cell limits, psychedelic efficacy gaps, AI in cancer care
Regulators confine stem cell therapy for autism to approved trials, psychedelic programs remain unproven, and AI reaches cancer clinics as a check on clinician oversight.
The week's health stories share a spine: the gap between a promising treatment and a proved one. Several items land on the not-yet side of that line; others show what it looks like to cross it.
When the evidence isn't in yet
Stem cell therapy for autism must be conducted only within approved clinical trials, the Centre for Cell Therapy and Regenerative Medicine announced, according to The Hindu's Health Matters newsletter. The framing is patient protection: restrictions of this kind keep people away from unproven medical treatments.
The same newsletter carried a blunter observation from Dr. Dinesh Arab: new, sophisticated drugs have failed to reduce the overall incidence of heart attacks and strokes. That is the uncomfortable edge of progress. Tools can improve without the population-level numbers following, and the newsletter's takeaway is that more effective cardiovascular interventions are still needed.
Psychedelic medicine sits in a similar holding pattern. Helus Pharma, until recently Cybin Inc., reported the results of its annual and special meeting held on September 22, 2026: shareholders approved a legal name change for the company and appointed a new auditor. What the announcement does not offer is proof. The company's focus on psychedelic compounds such as psilocin still lacks confirmed efficacy from approved research, and clinical trials are required to prove medical use, as Quiver Quantitative's report notes.
That caveat follows the company onto the conference circuit. Its CEO is scheduled to take part in a virtual mental-health summit on September 23, in a fireside chat webcast live at 9 a.m. EDT and later posted to the company's investor relations website, . The disclosure attached to the appearance is the part to read twice: the efficacy of the company's products, including HLP003 and HLP004, has not been confirmed by approved research, and rigorous scientific research and clinical trials are still required to determine whether these programs can diagnose, treat, cure, or prevent any disease. carries the same language.